-
Michael J. Fox Foundation Continues to Lead Search for Biomarkers of Parkinson's Disease
April 5, 2007
… NEWYORK, NY — The Michael J. Fox Foundation today announced the launch of Biomarkers 2007 , a two-year, … if results are negative) that are difficult to interpret. “Identification of markers that can address the … trials, or act as surrogate endpoints for clinical outcomes, would greatly improve our ability to develop and test …
-
Banding Together to Live Harder and Find a Cure
May 17, 2023
… Team Fox members worldwide are turning their passions into successful fundraising events — from hosting pancake … J. Fox Foundation (MJFF) asks our Do-It-Yourself (DIY) community about their experiences fundraising and creating … in raising awareness and funds for PD, but I wasn’t sure where to start. After a lot of consideration, I decided to …
-
Steps Closer to Stopping Parkinson's: 2021 Research Review
November 18, 2021
… Home Page Cancel Register for Webinar Steps Closer to Stopping Parkinson's: 2021 Research Review First Name … had PD I am a researcher, clinician or work with the PD community Other Diagnosis Date ${selected} Jan Feb Mar Apr … must have Javascript and Cookies enabled in your browser preferences to access this webinar. Privacy Policy Terms & …
-
Leaders in Parkinson’s Research Encouraged to Explore MJFF Collaboration
October 23, 2025
… Fiske, PhD, encourages researchers and industry leaders to collaborate with MJFF ahead of its annual Parkinson's … and how to get involved with our work. Designed to complement PDTC — the world’s only scientific conference … all of you working to help people with Parkinson’s everywhere.” De-Risking Science to Drive Therapeutic …
-
Treatment of Parkinson’s Disease with AT2101, a compound that increases the activity of endogenous Glucocerebrosidase
… and Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the gene GBA, which … in the lysosomes. Several studies have found an over-representation of GBA mutations among patient's with … Gaucher-associated and idiopathic Parkinson's. Final Outcome In year one, Amicus developed intriguing efficacy data …
-
Michael J. Fox Foundation Awards $1.9 Million to Support Ceregene Phase Ii Gene Therapy Clinical Trial
October 10, 2006
… for Parkinson’s Research (MJFF) will provide $1.9 million to support Ceregene Inc.’s Phase II study of CERE-120. This … nervous system trophic factor, has shown potential in preclinical studies to slow or stop Parkinson’s disease … neuroprotective effect in patients. The MJFF funding complements Ceregene’s own multi-million dollar investment …